Survival data of pirfenidone in the treatment of pulmonary fibrosis

Pirfenidone/Aisrei (Pirfenidone), whose domestic trade name is Aisrei, is one of the important anti-fibrosis drugs currently widely used in the treatment of idiopathic pulmonary fibrosis (IPF). Its main mechanism of action is to inhibit the expression of pro-fibrotic factors such as TGF-β and TNF-α, thereby slowing down the progression of pulmonary fibrous tissue hyperplasia and deterioration of lung function. Based on multiple studies and long-term follow-up data around the world, pirfenidone has been proven to significantly delay the progression of pulmonary fibrosis and improve the long-term survival of patients to a certain extent. Although it is not appropriate to cite specific clinical statistics at the moment, judging from the trend, patients treated with pirfenidone perform more actively in terms of disease stabilization rate and control of the rate of decline in vital capacity. Especially among the early intervention group, their survival benefit is more significant.

Overseas treatment guidelines state that pirfenidone is suitable for moderate to mild patients with confirmed IPFThe earlier the treatment is intervened, the more obvious clinical value it will have in delaying the end-stage manifestations of the disease, such as respiratory failure or dependence on oxygen therapy. Compared with patients who received no treatment or only supportive care, survival time and exacerbation-free time were significantly longer with pirfenidone, and the frequency of exacerbations was reduced. It is worth noting that although the drug does not reverse established fibrosis, it has become part of the current standard of care in maintaining lung function.

Therefore, in the context of the current lack of radical means, pirfenidone provides a therapeutic approach for patients with pulmonary fibrosis that can delay the progression of the disease and prolong survival. With the accumulation of clinical experience and the extension of medication time, pirfenidone's status as a first-line anti-fibrotic drug has become increasingly consolidated, bringing more hope of long-term benefits to IPF patients.

Reference materials:https://www.esbriet.com/